Panmira appoints chief executive

Hari Kumar will oversee inflammation portfolio

Panmira Pharmaceuticals, a developer of therapies for inflammatory diseases, based in San Diego, California, US, has appointed Hari Kumar as chief executive.

Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.

Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.

Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.

The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.

You may also like

Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Ingredients

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples
Research & Development

EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health

The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications
Research & Development

Biohm Technologies expands R&D footprint with new microbiome lab in Atlanta

The company has opened a state-of-the-art research lab at Portal Innovations’ Science Square campus in Atlanta, strengthening its microbiome R&D capabilities
Research & Development

Certain medicines accelerate elimination of PFAS from the body, Gothenburg study shows

Researchers at the University of Gothenburg have found that two cholesterol-lowering drugs, cholestyramine and colesevelam, can significantly speed up the removal of harmful PFAS chemicals from the body
Research & Development

Bioengineered bone marrow model successfully used in cancer research

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model in vital leukaemia research
Subscribe now